You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
ELECTRONIC COMPONENT PACKING DENSITY IS INCREASING RAPIDLY BECAUSE OF REQUIREMENTS FOR GREATER RELIABILITY, GREATER RESISTANCE TO VIBRATION AND SHORTER SIGNAL PATH.
SBC: Gas Curtain Technology Topic: N/AELECTRONIC COMPONENT PACKING DENSITY IS INCREASING RAPIDLY BECAUSE OF REQUIREMENTS FOR GREATER RELIABILITY, GREATER RESISTANCE TO VIBRATION AND SHORTER SIGNAL PATH. SMT TECHNIQUES, REPRESENTING STATE-OF-THEART, REQUIRE ADVANCED SOLDERING TECHNOLOGY INCLUDING DUAL-WAVE, IR, ULTRASONIC AND BLANKETED VAPOR PHASE SOLDERING. THE SHEER NUMBER OF SOLDER CONNECTIONS IN DAIC/PC WILL REQUIRE NEW EXTREMELY H ...
SBIR Phase I 1986 Department of DefenseNavy -
GASES
SBC: Gas Desulfurization Topic: N/ACLOSELY CONTROLLED LABORATORY RESULTS SHOW THAT CERIUM OXIDE CAN BE USED TO REDUCE THE H2S CONTENT OF FUEL GASES WITH A CO/C02 RATIO OF 5.1 FROM 10,000 PPM TO 3 TO 6 PPM AT 1601/2873F (872/1022C). THE SULFUR CONTAINING CERIUM COMPOUND WAS REGENERATED SO THAT IT WAS CAPABLE OF AGAIN REACTING WITH THE H2S. IT IS THE OBJECTIVE OF THIS PROPOSALTO DEMONSTRATE THE EXTENT OF DESULFURIZATION WITH CERIUM O ...
SBIR Phase I 1986 Department of Energy -
NEW APPROACHES TO PRODUCTION OF HLA TYPING REAGENTS
SBC: NEUGENESIS CORPORATION Topic: N/AHUMAN CLASS II HISTOCOMPATIBILITY ANTIGEN TYPING IS ALREADY OF SUBSTANTIAL IMPORTANCE IN DETERMING DISEASE SUSCEPTIBILITY IN INDIVIDUALS. PRESENT SEROLOGIC METHODS OF CLASS II ANTIGEN TYPING ARE LIMITED BY THE POLYCLONAL NATURE OF MANY ANTISERA, BY THE FACT THAT MANY OF THE AVAILABLE HUMAN ANTISERA REACT WITH MULTIPLE DIFFERENT DETERMINANTS AND BY THE DIFFICULTY OF OBTAINING ALLELE SPECIFIC AS COM ...
SBIR Phase II 1986 Department of Health and Human Services -
HUMAN MONOCLONAL ANTIBODIES TO HLA-DR DETERMINANTS
SBC: NEUGENESIS CORPORATION Topic: N/ATHE IMMUNE RESPONSE IN MAN IS REGULATED BY ORDERED INTERACTIONS BETWEEN FUNCTIONALLY AND PHENOTYPICALLY DISTINCT LYMPHOID CELLS (T CELLS AND THEIR SUBSETS, B CELLS AND MONOCYTES) IN THE CONTEXT OF IA-LIKE MOLECULES ENCODED BY THE HLA COMPLEX OF GENES. THUS, THE PRODUCTS OF THESE GENES (E.G., DR, DS, SB) CONTROL THE PROLIFERATIVE RESPONSE OF T CELLS IN MIXED LYMPHOCYTE REACTIONS, ANTIGEN PRESENTATI ...
SBIR Phase II 1986 Department of Health and Human Services -
UNTIL VERY RECENTLY, THE SIZES OF DNA FRAGMENTS THAT COULD BE DEALT WITH BY CLONING AND ELECTROPHORETIC TECHNIQUES WEREGENERALLY ONE TO TWO ORDERS OF MAGNITUDE BELOW THOSE NEEDED FOR A PRACTICAL AND SYSTEMATIC MOLECULAR DESCRIPTION OF HUMAN DNA
SBC: NEUGENESIS CORPORATION Topic: N/AUNTIL VERY RECENTLY, THE SIZES OF DNA FRAGMENTS THAT COULD BE DEALT WITH BY CLONING AND ELECTROPHORETIC TECHNIQUES WEREGENERALLY ONE TO TWO ORDERS OF MAGNITUDE BELOW THOSE NEEDED FOR A PRACTICAL AND SYSTEMATIC MOLECULAR DESCRIPTION OF HUMAN DNA RELATIONSHIPS OVER THE RANGE DEALT WITH BY CLASSICAL GENETIC AND CYTOLOGIC ANALYSIS. RECENT DEVELOPMENTS, INCLUDING PULSE FIELD GRADIENT ELECTROPHORESISAND ...
SBIR Phase I 1986 Department of Health and Human Services -
MONOCLONAL ANTIBODIES TO HTLV-III/LAV
SBC: NEUGENESIS CORPORATION Topic: N/AMOUSE AND RAT MONOCLONAL ANTIBODIES WILL BE PRODUCED AGAINSTHTLV-III, THE HUMAN RETROVIRUS ASSOCIATED WITH AIDS AND A SPECTRUM OF RELATED SYNDROMES. GENE LABS WILL EMPLOY INTACTHTLV-III VIRIONS COUPLED TO KLH AS AN IMMUNOGEN AND USE A SENSITIVE ELISA ASSAY, BASED ON PURIFIED HTLV-III AS THE ANTIGEN IN OUR PRIMARY SCREENING PROCEDURE. IMMUNOPRECIPI- TATION, WESTERN BLOTTING, AND CELLULAR IMMUNOFLUO ...
SBIR Phase I 1986 Department of Health and Human Services -
IN THIS PROJECT, GENE LABS, INC.
SBC: NEUGENESIS CORPORATION Topic: N/AIN THIS PROJECT, GENE LABS, INC. WILL PRODUCE AND CHARACTERIZE HUMAN MONOCLONAL ANTIBODIES TO HTLV-III, THE HUMAN RETROVIRUS ASSOCIATED WITH AIDS AND A SPECTRUM OF RELATED SYNDROMES. GENE LABS HAS SUCCESSFULLY USED THE SBC-H20 HETEROMYELOMA CELL LINE AS THE FUSION PARTNER FOR THE GENERATION OF SEVERAL STABLE, IMMUNOGLOBULIN-SECRETING HUMAN B CELL HYBRIDOMAS, INCLUDING ONE DIRECTED AGAINST AN HTLV- ...
SBIR Phase I 1986 Department of Health and Human Services -
THE GOAL OF THIS PROPOSED RESEARCH IS TO DEFINE THE MOLECU- LAR STRUCTURES THAT DETERMINE THE ANTIGENETIC REACTIVITY OF THE HUMAN RH SYSTEM.
SBC: NEUGENESIS CORPORATION Topic: N/ATHE GOAL OF THIS PROPOSED RESEARCH IS TO DEFINE THE MOLECU- LAR STRUCTURES THAT DETERMINE THE ANTIGENETIC REACTIVITY OF THE HUMAN RH SYSTEM. USING PREEXISTING HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST A LARGE G DETERMINANT AND ONE DIRECTED AGAINST A DETERMINANT FOUND ON RH D+ CELLS BUT NOT DU CELLS, GENE LABS WILL REFINE THE CHARACTERIZATION OF THE HUMAN RH SYSTEM. IN ADDITION TO THE ABOVE ANTI ...
SBIR Phase I 1986 Department of Health and Human Services -
THEIR POTENTIAL APPLICATIONS TO A SUBUNIT VACCINE
SBC: NEUGENESIS CORPORATION Topic: N/AHUMAN T-CELL LYMPHOTROPHIC VIRUS TYPE I (HTLV-I) IS THE CAUSATIVE AGENT OF AN AGGRESSIVE FORM OF T-CELL LEUKEMIA ENDEMIC TO CERTAIN GEOGRAPHIC AREAS BUT ALSO CURRENTLY INCREASING IN FREQUENCY IN THE SAME POPULATION AT RISK FOR DEVELOPING AIDS. SERO-EPIDEMIOLOGIC DATA SUGGEST THE PRESENCE OF A TYPE-COMMON NEUTRALIZATION DETERMINANT. THIS PROPOSAL SEEKS TO IDENTIFY AND PRODUCE, BY USE OF A RECOMBINA ...
SBIR Phase I 1986 Department of Health and Human Services -
THIS PROJECT WILL PRODUCE MOUSE AND RAT MONOCLONAL ANTIBODIES TO THE LEUKEMOGENIC HUMAN RETROVIRUS, HTLV-I.
SBC: NEUGENESIS CORPORATION Topic: N/ATHIS PROJECT WILL PRODUCE MOUSE AND RAT MONOCLONAL ANTIBODIES TO THE LEUKEMOGENIC HUMAN RETROVIRUS, HTLV-I. STABLE, IMMUNOGLOBULIN-SECRETING HTLV-I ELISA-REACTIVE SUBCLONES WILL BE ISOLATED AND THEIR VIRAL ANTIGEN SPECIFICITY CONFIRMED BY IMMUNOPRECIPITATION, WESTERN BLOTTING, AND IMMUNOFLUORESCENCE ANALYSIS. THE BINDING CONSTANTS OF THE ANTIBODIES PRODUCED WILL BE DETERMINED. ITIS ANTICIPATED THA ...
SBIR Phase I 1986 Department of Health and Human Services